Amgen may buy cancer drug maker Onyx for $10.5B

August 25, 2013

Biotech drugmaker Amgen is reportedly close to buying cancer drug maker Onyx Pharmaceuticals for about $10.5 billion.

The New York Times reported Saturday that Amgen Inc. would buy Onyx for $125 per share. It cited people familiar with the matter. Onyx declined to comment, while Amgen did not immediately respond to inquiries.

Amgen's drugs includes Prolia for osteoporosis, Enbrel for rheumatoid arthritis and skin disorders, and Neulasta and Neupogen for fighting infection in cancer patients.

Onyx Pharmaceuticals Inc. markets a liver and pill called Nexavar through a partnership with Bayer AG. Sales totaled about $861 million in 2012. In July the regulators approved Onyx's Kyprolis as a treatment for a type of blood cancer.

Onyx rejected an offer from Amgen of $120 per share in June.

Explore further: Amgen 2Q net dips on higher research, other costs (Update)

Related Stories

Amgen 2Q net dips on higher research, other costs (Update)

July 30, 2013
Amgen Inc. said Tuesday that its second-quarter profit dipped 1 percent as higher spending on research, production and other items offset rising sales of its medicines.

FDA panel unanimously backs Onyx cancer drug

June 21, 2012
(AP) — A federal panel of cancer specialists on Wednesday unanimously recommended approval of an experimental drug from Onyx Pharmaceuticals Inc. for patients with advanced blood cancer.

Amgen 4Q profit drops 16 pct. on higher spending

January 23, 2013
Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results ...

US focuses on toxic side effects with Onyx drug

June 18, 2012
(AP) — The toxic side effects of an experimental cancer drug from Onyx Pharmaceuticals may outweigh its benefits for patients with a type of blood cancer, federal health regulators said Monday.

Sales disappoint, but tax gain lifts Amgen profit

April 23, 2013
Tax credits helped biotech giant Amgen report first-quarter earnings that beat Wall Street's expectations, but sales growth disappointed investors.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.